Related Experiment Video
Updated: May 17, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Alzheimer disease in 2020
David M Holtzman1, Eckhard Mandelkow, Dennis J Selkoe
1Department of Neurology, Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA. holtzman@neuro.wustl.edu
Cold Spring Harbor Perspectives in Medicine
|November 6, 2012
Summary
Despite significant progress in understanding Alzheimer disease (AD) biology, effective disease-modifying treatments remain elusive. This review predicts key research areas for AD in the next decade, focusing on unresolved questions.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Over the past 25 years, substantial advancements have been made in understanding the biological mechanisms underlying Alzheimer disease (AD).
- Despite these biological insights, the development of effective disease-modifying treatments for AD has seen limited success.
Purpose of the Study:
- To predict the future landscape of Alzheimer disease research and treatment development over the next decade.
- To identify key unresolved questions and areas requiring focused investigation in the coming 10 years.
Main Methods:
- The study is a predictive review based on existing knowledge from a collection of contributions.
- It synthesizes current understanding to forecast future research directions and challenges.
Main Results:
- The review highlights the persistent gap between biological understanding and therapeutic success in Alzheimer disease.
- It identifies critical areas for future research, emphasizing the need for novel approaches.
Conclusions:
- Significant challenges remain in translating basic science discoveries into effective Alzheimer disease therapies.
- Future research must prioritize addressing fundamental unresolved questions to accelerate the development of disease-modifying treatments.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...